SAN DIEGO, Aug. 22, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional
detailed pre-clinical pharmacology and pharmacokinetic data on
ralinepag (APD811), the Company's next-generation, oral, selective
prostacyclin receptor (IP) agonist intended for the treatment of
pulmonary arterial hypertension (PAH), on August 29 at the European Society of Cardiology
Congress (ESC) 2017. ESC is taking place August 26 – 30 at the Fira Gran Via in
Barcelona, Spain.
The presentations will comprise ralinepag IP receptor binding
affinity, selectivity and comparative functional potency versus
approved IP agonists. Biological responses highlighting the
pharmacology and pharmacokinetics of ralinepag in rat PAH models,
human platelets, human pulmonary arteries and human pulmonary
artery smooth muscle cells from PAH patients will be presented.
"The pre-clinical pharmacology data continue to support our
belief that ralinepag is a potential best-in-class oral
prostacyclin therapy," said Amit D.
Munshi, President and Chief Executive Officer of Arena. "The
acceptance of the scientific data presentation at ESC is
representative of the enthusiasm of clinical investigators and
scientists to continue exploring the novel profile of
ralinepag."
Presentation Details
Title: Comparative receptor
pharmacology, preclinical efficacy and pharmacokinetics of a novel,
next-generation prostacyclin receptor agonist, ralinepag (APD811),
in humans and rats
Session: Progress in the management of
pulmonary hypertension
Date/Time: Tuesday, August 29,
11:18 a.m. CET
Rapid Fire Abstract: 5019
Location: Agora 1 – Agora
Title: APD811 (ralinepag), a novel non-prostanoid IP receptor
agonist, has potent antiproliferative and vasorelaxant properties
in human pulmonary artery
Session: Progress in the
management of pulmonary hypertension
Date/Time: Tuesday, August 29,
11:36 a.m. CET
Rapid Fire Abstract: 5021
Location: Agora 1 – Agora
About Arena Pharmaceuticals
Arena Pharmaceuticals is a
biopharmaceutical company focused on developing novel, small
molecule drugs with optimized receptor pharmacology designed to
deliver broad clinical utility across multiple therapeutic areas.
Our proprietary pipeline includes potentially first- or
best-in-class programs for which we own global commercial rights.
Our three most advanced investigational clinical programs are
ralinepag (APD811) which has completed a Phase 2 trial for
pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase
2 evaluation for multiple autoimmune indications, and APD371 in
Phase 2 evaluation for the treatment of pain associated with
Crohn's disease. In addition, Arena has collaborations with the
following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These statements may be identified by
introductory words such as "intended," "will," "belief,"
"potential," "designed" or words of similar meaning, or by the fact
that they do not relate strictly to historical or current facts.
Such forward-looking statements include statements about the
upcoming presentations, the potential of ralinepag, advancement of
our pipeline, our focus, and the potential of our programs and
collaborations. For such statements, we claim the protection
of the Private Securities Litigation Reform Act of 1995. Actual
events or results may differ materially from our expectations.
Factors that could cause actual results to differ materially from
the forward-looking statements include: the timing and outcome of
research, development and regulatory review is uncertain; enrolling
patients in our ongoing and intended clinical trials is competitive
and challenging; we expect to need additional funds to advance all
of our programs, and you and others may not agree with the manner
we allocate our resources; our drug candidates may not advance in
development or be approved for marketing; risks related to
developing and commercializing drugs; the risk that Arena's
revenues are based in part on estimates, judgment and accounting
policies, and incorrect estimates or disagreement regarding
estimates or accounting policies may result in changes to Arena's
guidance or previously reported results; government and third-party
payor actions, including relating to reimbursement and pricing;
risks related to relying on collaborative arrangements; the entry
into or modification or termination of collaborative arrangements;
unexpected or unfavorable new data; nonclinical and clinical data
are voluminous and detailed, and regulatory agencies may interpret
or weigh the importance of data differently and reach different
conclusions than Arena or others, request additional information,
have additional recommendations or change their guidance or
requirements before or after approval; topline data may not
accurately reflect the complete results of a particular study or
trial; Arena's and third parties' intellectual property rights;
results of clinical trials and other studies are subject to
different interpretations and may not be predictive of future
results; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; satisfactory resolution
of litigation or other disagreements with others; and those factors
disclosed in our filings with the Securities and Exchange
Commission, including our Form 10-Q for the quarter ended
June 30, 2017. These forward-looking
statements represent our judgment as the time of this release. We
disclaim any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-additional-pre-clinical-data-on-ralinepag-for-treatment-of-pulmonary-arterial-hypertension-at-european-society-of-cardiology-congress-300507300.html
SOURCE Arena Pharmaceuticals, Inc.